Skip to content

Correlation between exercise intensity and serum BDNF, CREB and spasm prognosis in SCI patients

Correlation between exercise intensity and serum BDNF, CREB and spasm prognosis in SCI patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800016653
Enrollment
Unknown
Registered
2018-06-14
Start date
2018-07-01
Completion date
Unknown
Last updated
2018-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

spinal cord injury

Interventions

low intensity exercise treatment group:conventional therapy and low intensity exercise
moderate intensity exercise treatment group:conventional therapy and moderate intensity exercise
high intensity exercise treatment group:conventional therapy and high intensity exercise
control group:conventional therapy

Sponsors

The First Affiliated Hospital, Nanjing Medical University (Jiangsu Province Hospital)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-65 years old; 2. confirmed by CT or MRI, the flat surface of the spinal cord was T7-L1, AIS B and AIS C(ASIA grade); 3. the course of the disease was 3-12 months, and there were different degrees of lower limb spasm; 4. passive range of hip and knee joints was approximately normal and did not affect Motomed treadmill training; 5. patients can understand and actively participate in the training program, agreed and signed the informed consent of the clinical study; 6. if anti-spasticity drugs were used, the stability use of the drug like dosage had already used for more than 1 month.

Exclusion criteria

Exclusion criteria: 1. ischemic heart disease, arrhythmia, unstable angina; 2. severe chronic obstructive pulmonary disease; 3. combined with lower extremity fractures; 4. combined with peripheral nerve injury of the lower extremities; 5. combined history of stroke; 6. severely limited range of motion of joints, limited Motomed treadmill training; 7. Pregnancy or breastfeeding women; 8. Need to use nerve blockage at any time during the trial; 9. Neurotranscision such as botulinum toxin or alcohol within 3 months before the start of the trial.

Design outcomes

Secondary

MeasureTime frame
H - Max/M - Max ratio;RDD value;motor evoked potential (MEP);somatosensory evoked potential (SEP);

Primary

MeasureTime frame
ASIA grade;Lower limb muscle strength;activity of daily living (ADL);Modified Ashworth Scale (MAS);Modified Tardieu Scale (MTS);Brain-derived Neurotrophic Factor (BDNF);calcium/cyclic-AMP responsive binding protein (CREB);

Countries

China

Contacts

Public ContactWang Hongxing

The First Affiliated Hospital, Nanjing Medical University (Jiangsu Province Hospital)

wanghongxing@njmu.edu.cn+86 13770823776

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026